Clinical Trials 2010 - Frankfurt

North West Business Group29 - 30 September 2010, Frankfurt, Germany.
In the current environment where minimising cost and delivering ROI are critical themes within the pharma industry, improving your clinical trial infrastructure can ensure that time is not wasted and you are maximising your investments. Attend Clinical trials 2010, this two day meeting which is concise and packed with value, Presentations that will be case-study oriented, supplemented by panel discussions and network with leading practitioners to provide information to keep clinical trials goal-oriented, on-time and cost-effective. Take-aways will include presentations with information that can readily be adapted to clinical trial projects in your organization.The 2010 event is set to be a highlight in the clinical trial events calendar. What's more, it is widely accepted that there is nothing better than to learn from the experience of experts rather than trying to build that knowledge yourself.

The programme covers a wide range of topics including:

  • Clinical Trials in the 21st Century
  • Clinical trials in emerging economies: myth and reality
  • How to optimize the global patient recruitment process
  • Working with Academic Study Groups
  • How to attract and retain clinical trials in western countries
  • Outsourcing Innovative approaches
  • The effect of EU regulations on conducting clinical trials

Joins some of the experts like:

  • Astrazeneca, Clinical Research Director Europe
  • Grunenthal, Head of Clinical Operations
  • MDC, Senior PartnerProduct Specialist Clinical Business Intelligence Systems
  • Novartis, Chief Scientific Officer
  • Glaxo Smith Kline, Director Clinical Research
  • Actelion, Director, Global Clinical Development Affairs
  • Novartis, Head Clinical Operations
  • Lundbeck, Senior Specialist, Outsourcing
  • Janssen-Cilag, Head Clinical Trials
  • Sanofi-Aventis, Head of Clinical Research Unit
  • Bayer Health care, EDC Director
  • Pfizer, Associate Director Worldwide Regulatory Affairs & Quality Assurance
  • And many more...

Who should attend?
This conference is designed to attract key decision makers from the Pharmaceutical industry: Presidents, Managing Directors, Country Managers, General Managers, Vice Presidents, Regional Directors/ Heads, Directors, Department Heads, Managers.

For further information and registration, please visit:
http://nwbg.eu/all-events/clinical-trials-2010/

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Consuming milk at breakfast lowers blood glucose t…

A change in breakfast routine may provide benefits for the management of type 2 diabetes, according to a new study published in the Journal of Dairy Science. H. Douglas G...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Bristol-Myers Squibb - Pfizer Alliance ACROPOLIS™ …

The Bristol-Myers Squibb-Pfizer Alliance will present 15 Eliquis® (apixaban) posters at the ESC Congress 2018 held in Munich, Germany, August 25-29, 2018. Nine of the pos...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...